FDA gives AbbVie’s c-Met lung cancer ADC a breakthrough tag
pharmaphorum
JANUARY 5, 2022
Novartis’ Tepmetko (tepotinib) was approved b the FDA last year for both treatment naïve and previously treated METex14 positive NSCLC patients, as was Merck’s Tabrecta (capmatinib), while Hutchmed’s Orpathys (savolitinib) has been approved as a second-line option in China.
111 
Let's personalize your content